Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803803 · ClinicalTrials.gov registry record · Phase 4
Dose, Effects and Characteristics of Pilocarpine
A Phase 4 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT00803803: Completed Phase 4 study, sponsored by Wills Eye.
NCT00803803 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 37 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00803803, a Phase 4 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: Part I - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. Part II -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when given once, twice and four daily. In addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.
Interventions
- DRUG Pilocarpine Concentration
- DRUG Pilocarpine Frequency
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 1978-08 |
| Est. Completion | 1979-12 |
| Phase | Phase 4 |
What the finished NCT00803803 record still lists
NCT00803803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Pilocarpine Concentration is the first listed.
NCT00803803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00803803 about?
NCT00803803 is a clinical study titled "Dose, Effects and Characteristics of Pilocarpine". The purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: Part I - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. Part II -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when gi...
What is the current status of trial NCT00803803?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 1978-08. Estimated completion is 1979-12.
What interventions are being tested in trial NCT00803803?
The interventions under investigation include: Pilocarpine Concentration (DRUG), Pilocarpine Frequency (DRUG).
Who is sponsoring clinical trial NCT00803803?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00803803's enrollment target sits among peer trials
37 1482nd of 2000 higher than 511 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia